Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function.

about

Bendamustine in multiple myeloma.

P2860

Q38530583-CA5084BC-2994-45CD-9197-E0F89390AEDB

P2860

Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function.

Item

http://www.wikidata.org/entity/Q52958098

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Dose-intensified bendamustine ...... impaired bone marrow function.

@en

Dose-intensified bendamustine ...... impaired bone marrow function.

@nl

type

Item

label

Dose-intensified bendamustine ...... impaired bone marrow function.

@en

Dose-intensified bendamustine ...... impaired bone marrow function.

@nl

prefLabel

Dose-intensified bendamustine ...... impaired bone marrow function.

@en

Dose-intensified bendamustine ...... impaired bone marrow function.

@nl

P1476

Dose-intensified bendamustine ...... impaired bone marrow function.

@en

P2093

Anthony D Ho

http://www.w3.org/2001/XMLSchema#string

Axel Benner

http://www.w3.org/2001/XMLSchema#string

Christoph Heining

http://www.w3.org/2001/XMLSchema#string

Florentina Kosely

http://www.w3.org/2001/XMLSchema#string

Gerlinde Egerer

http://www.w3.org/2001/XMLSchema#string

Iris Breitkreutz

http://www.w3.org/2001/XMLSchema#string

Jens Hillengass

http://www.w3.org/2001/XMLSchema#string

Marc S Raab

http://www.w3.org/2001/XMLSchema#string

Natalia Becker

http://www.w3.org/2001/XMLSchema#string

P2860

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.

Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.

International staging system for multiple myeloma.

P304

200-207

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HON.2199

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hartmut Goldschmidt

P577

2015-03-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25784529

http://www.w3.org/2001/XMLSchema#string

Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function.

about

P2860

P2860

Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698